Oncology
Myeloproliferative Neoplasms 2011 – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, provides an update on Myeloproliferative Neoplasms
A quote for you...
Powered By Optimism Quotes
Florida Premier Research Institute
Florida Premier Research Institute, and Florida Pulmonary Research Institute are State-of-the-Art, Multi-Specialty facilities conducting Phase I-IV clinical trials in the Orlando, Florida, metropolitan area. Our Principal Investigator, Dr. Faisal A. Fakih and staff are fully committed to finding new medical treatments to improve the millions of lives affected by a… Continue reading
Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
Charles Hugh-Jones, MD, Vice President, Head of Medical Oncology Affairs, Sanofi North America, discusses the results of a phase I/II study looking at SAR302503, an investigational oral JAK2-selective inhibitor for patients with myelofibrosis. The trial enrolled 59 patients; 44 with primary myelofibrosis, 12 post-polycythemia vera, and 4 post-essential thrombocythemia. 86%… Continue reading
Dr. Ruben Mesa Discusses the COMFORT Ruxolitinib Trials
Ruben A. Mesa, MD, Professor of Medicine, Chair, Division of Hematology & Medical Oncology, Mayo Clinic, Arizona, discusses the phase III Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) trials, which led to the FDA approval of ruxolitinib (Jakafi) for patients with myelofibrosis. COMFORT-I was a placebo controlled studied… Continue reading
Jakafi – FDA Approves Incyte’s Jakafi™ (ruxolitinib) for Patients with Myelofibrosis
Dan of Point Pleasant, South Carolina, reacts to the approval of Jakafi(TM). www.businesswire.com
Short and sweet, but says it all for those myelofibrosis sufferers who are able to access it and benifit from it.
A quote for you...
Powered By Optimism Quotes
FDA Approves Incyte’s Jakafi™ (ruxolitinib) for Patients with Myelofibrosis
Dr. Srdan Verstovsek, MD Anderson Cancer Center, discusses myelofibrosis. www.businesswire.com
A quote for you...
Powered By Optimism Quotes
FDA Approves Incyte’s Jakafi™ (ruxolitinib) for Patients with Myelofibrosis
Paul Friedman, President and CEO, Incyte, discusses the FDA approval of Jakafi(TM). www.businesswire.com
A quote for you...
Powered By Optimism Quotes
Interferon for Myeloproliferative Neoplasms: Current and Future Uses – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, discusses the latest on Interferon for Myeloproliferative Neoplasms
A quote for you...
Powered By Optimism Quotes
Myeloproliferative Neoplasms 2011 – Mayo Clinic
Hematologist Ruben Mesa, MD, Chair, Division of Hematology and Oncology at Mayo Clinic in Arizona, provides an update on Myeloproliferative Neoplasms
A quote for you...
Powered By Optimism Quotes